A phase 2a, open-label study of visilizumab in patients with moderate-to-severe inflammatory, nonstricturing, nonpenetrating forms of Crohn's disease.

Trial Profile

A phase 2a, open-label study of visilizumab in patients with moderate-to-severe inflammatory, nonstricturing, nonpenetrating forms of Crohn's disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2012

At a glance

  • Drugs Visilizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors PDL BioPharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jul 2011 Status changed from discontinued to completed as reported by ISRCTN: Current Controlled Trials record.
    • 28 May 2011 Additional trial locations (Germany, Netherlands) identified as reported by ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top